{"id":10377,"date":"2026-06-30T10:41:44","date_gmt":"2026-06-30T02:41:44","guid":{"rendered":"https:\/\/regask.com\/?p=10377"},"modified":"2026-06-30T10:41:44","modified_gmt":"2026-06-30T02:41:44","slug":"precios-de-medicamentos-y-acceso-al-mercado-junio-de-2026","status":"publish","type":"post","link":"https:\/\/regask.com\/es\/drug-pricing-market-access-june-2026\/","title":{"rendered":"Precios de medicamentos y acceso al mercado en 2026: Negociaci\u00f3n de Medicare\u2026"},"content":{"rendered":"<p id=\"ember1956\" class=\"ember-view reader-text-block__paragraph\"><span class=\"TextRun SCXW232482172 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><strong><span class=\"NormalTextRun SCXW232482172 BCX0\">Los precios de los medicamentos y el acceso al mercado se trasladaron a la\u00a0<\/span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW232482172 BCX0\">centro<\/span><span class=\"NormalTextRun SCXW232482172 BCX0\">\u00a0de la regulaci\u00f3n farmac\u00e9utica a mediados de 2026, a medida que el enfoque pas\u00f3 del registro al financiamiento<\/span><span class=\"NormalTextRun SCXW232482172 BCX0\">,<\/span><\/strong><span class=\"NormalTextRun SCXW232482172 BCX0\"><strong>\u00a0Precios, financiaci\u00f3n y evaluaci\u00f3n de tecnolog\u00edas sanitarias.<\/strong> Estados Unidos avanz\u00f3 en su marco de negociaci\u00f3n de precios de Medicare, Espa\u00f1a abri\u00f3 una consulta sobre precios de medicamentos y Portugal\u00a0<\/span><span class=\"NormalTextRun SCXW232482172 BCX0\">formalizado<\/span><span class=\"NormalTextRun SCXW232482172 BCX0\">\u00a0Un r\u00e9gimen nacional de evaluaci\u00f3n de tecnolog\u00edas sanitarias, todo en el mismo mes. Esta es la etapa del ciclo de vida en la que un producto perfectamente aprobable a\u00fan puede fracasar comercialmente, y la brecha entre la aprobaci\u00f3n y el acceso se est\u00e1 ampliando.<\/span><\/span><span class=\"EOP Selected SCXW232482172 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:0,&quot;335559739&quot;:0}\">\u00a0<\/span><\/p>\n\t<div id=\"gap-1208551591\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1208551591 {\n  padding-top: 20px;\n}\n<\/style>\n\t<\/div>\n\t\n<h3><strong><span class=\"TextRun MacChromeBold SCXW167568299 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW167568299 BCX0\">Estados Unidos ampli\u00f3 la negociaci\u00f3n de precios de medicamentos de Medicare.<\/span><\/span><\/strong><\/h3>\n\t<div id=\"gap-1538746632\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1538746632 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"NormalTextRun SCXW16343997 BCX0\">Los Centros de Servicios de Medicare y Medicaid publicaron una propuesta de norma que abarca el Programa de Negociaci\u00f3n de Precios de Medicamentos de Medicare y el Plan de Pago de Recetas de Medicare. La negociaci\u00f3n de precios ha transformado la planificaci\u00f3n comercial de EE. UU. desde su introducci\u00f3n, y cada expansi\u00f3n ampl\u00eda el conjunto de\u00a0<\/span><span class=\"NormalTextRun SCXW16343997 BCX0\">productos,<\/span><span class=\"NormalTextRun SCXW16343997 BCX0\">\u00a0y el\u00a0<\/span><span class=\"NormalTextRun SCXW16343997 BCX0\">mec\u00e1nica&#039;\u2019<\/span><span class=\"NormalTextRun SCXW16343997 BCX0\">\u00a0Los fabricantes deben modelar. Estrategia de precios, secuencia de lanzamiento y planificaci\u00f3n del ciclo de vida ahora.\u00a0<\/span><span class=\"NormalTextRun SCXW16343997 BCX0\">debe<\/span><span class=\"NormalTextRun SCXW16343997 BCX0\">\u00a0Considerar el riesgo de negociaci\u00f3n en lugar de tratarlo como un caso excepcional. Las empresas que se adaptan primero incorporan escenarios de negociaci\u00f3n en sus pron\u00f3sticos; las dem\u00e1s ven c\u00f3mo sus suposiciones se ven superadas.<\/span><\/p>\n<h3><strong><span class=\"TextRun MacChromeBold SCXW86240589 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW86240589 BCX0\">Espa\u00f1a avanz\u00f3 en la reforma de precios y financiaci\u00f3n.<\/span><\/span><\/strong><\/h3>\n\t<div id=\"gap-34183205\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-34183205 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"NormalTextRun SCXW22514267 BCX0\">El Ministerio de Sanidad espa\u00f1ol ha abierto una consulta sobre un proyecto de Real Decreto que actualiza la forma en que se fijan los precios y se financian los medicamentos. Las consultas sobre la reforma de precios representan tanto una oportunidad como un riesgo.\u00a0<\/span><span class=\"NormalTextRun SCXW22514267 BCX0\">(<\/span><span class=\"NormalTextRun SCXW22514267 BCX0\">la ventana de oportunidad para participar antes de que las reglas se endurezcan<\/span><span class=\"NormalTextRun SCXW22514267 BCX0\">)<\/span><span class=\"NormalTextRun SCXW22514267 BCX0\">, pero<\/span><span class=\"NormalTextRun SCXW22514267 BCX0\">\u00a0Tambi\u00e9n indican que se est\u00e1n redefiniendo los criterios de reembolso. Las empresas que operan en el mercado espa\u00f1ol o que planean hacerlo deber\u00edan leer detenidamente el borrador, analizar las implicaciones financieras y aprovechar el periodo de consulta para presentar sus argumentos. Participar ahora es mucho m\u00e1s econ\u00f3mico que renegociar los precios posteriormente.<\/span><\/p>\n<h3><strong><span class=\"NormalTextRun SCXW80489494 BCX0\">Portugal\u00a0<\/span><span class=\"NormalTextRun SCXW80489494 BCX0\">establecido<\/span><span class=\"NormalTextRun SCXW80489494 BCX0\">\u00a0un marco nacional de evaluaci\u00f3n de tecnolog\u00edas sanitarias<\/span><\/strong><\/h3>\n\t<div id=\"gap-2109932904\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-2109932904 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"TextRun SCXW253334816 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW253334816 BCX0\">Portugal public\u00f3 el Decreto Ley 118\/2026.\u00a0<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">estableciendo<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">\u00a0un r\u00e9gimen nacional de evaluaci\u00f3n de tecnolog\u00edas sanitarias,\u00a0<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">formalizaci\u00f3n<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">\u00a0c\u00f3mo se eval\u00faan los nuevos medicamentos y tecnolog\u00edas para su reembolso. La HTA es cada vez m\u00e1s la verdadera puerta de acceso en Europa: la aprobaci\u00f3n otorga una\u00a0<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">licencia<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">, pero HTA decide si el sistema paga. A\u00a0<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">formalizado<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">\u00a0marco significa anterior, m\u00e1s estructurado\u00a0<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">evidencia de<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">\u00a0<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">demandas;<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">\u00a0<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">Los datos econ\u00f3micos y sanitarios, as\u00ed como la eficacia comparativa, deben planificarse durante el desarrollo, y no recopilarse en el momento del lanzamiento, cuando el dise\u00f1o del ensayo y los comparadores ya est\u00e1n definidos.<\/span><\/span><span class=\"EOP SCXW253334816 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:0,&quot;335559739&quot;:0}\">\u00a0<\/span><\/p>\n<h3><strong><span class=\"NormalTextRun SCXW227434142 BCX0\">Qu\u00e9\u00a0<\/span><span class=\"NormalTextRun ContextualSpellingAndGrammarErrorV2Themed SCXW227434142 BCX0\">este<\/span><span class=\"NormalTextRun SCXW227434142 BCX0\">\u00a0<\/span><span class=\"NormalTextRun ContextualSpellingAndGrammarErrorV2Themed SCXW227434142 BCX0\">medio<\/span><span class=\"NormalTextRun SCXW227434142 BCX0\">\u00a0para\u00a0<\/span><span class=\"NormalTextRun SCXW227434142 BCX0\">Farmacia<\/span><\/strong><\/h3>\n\t<div id=\"gap-1091164157\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1091164157 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"TextRun SCXW97054545 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW97054545 BCX0\">En Estados Unidos, Espa\u00f1a y Portugal, el mensaje es consistente: obtener la aprobaci\u00f3n ya no es la parte dif\u00edcil.<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">,\u00a0<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">Cobrar es. Traer\u00a0<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">acceso al mercado<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">\u00a0Pensando en el futuro. Modelar la exposici\u00f3n a la negociaci\u00f3n de precios en los EE. UU., participar en consultor\u00edas de precios como la de Espa\u00f1a, mientras\u00a0<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">ellos son<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">\u00a0abrir y generar evidencia de grado HTA temprana para los mercados.\u00a0<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">formalizaci\u00f3n<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">\u00a0evaluaci\u00f3n. La estrategia de acceso ahora debe formar parte de la planificaci\u00f3n del desarrollo junto con el programa cl\u00ednico.<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">s<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">, no en la carrera posterior a la aprobaci\u00f3n donde\u00a0<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">evidencia de<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">\u00a0opciones\u00a0<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">tiene<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">\u00a0ya se ha reducido.\u00a0<\/span><strong><a href=\"http:\/\/regask.com\/es\/\"><span class=\"NormalTextRun SpellingErrorV2Themed SCXW97054545 BCX0\">RegASK<\/span><\/a><\/strong><span class=\"NormalTextRun SCXW97054545 BCX0\">\u00a0Supervisa los precios, los reembolsos y la evoluci\u00f3n de las evaluaciones de tecnolog\u00edas sanitarias en los mercados globales, ayudando a los equipos de regulaci\u00f3n y acceso al mercado.\u00a0<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">plan<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">\u00a0barreras de acceso antes\u00a0<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">lanzamiento<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">.<\/span><\/span><span class=\"EOP SCXW97054545 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:0,&quot;335559739&quot;:0}\">\u00a0<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>Drug pricing and market access moved to the\u00a0centre\u00a0of pharma regulation in mid-2026, as the focus shifted from registration to money,\u00a0pricing, financing, and health technology assessment. The US advanced its Medicare price-negotiation framework, Spain opened a consultation on drug pricing, and Portugal\u00a0formalized\u00a0a national HTA regime, all in the same month. This is the part of the&#8230;<\/p>","protected":false},"author":46,"featured_media":10378,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-10377","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blogs"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.8 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Drug Pricing and Market Access Explained in 2026<\/title>\n<meta name=\"description\" content=\"Explore the challenges of drug pricing and market access in a changing regulatory landscape. Understand the impact on commercialization.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/es\/precios-de-medicamentos-y-acceso-al-mercado-junio-de-2026\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Drug Pricing &amp; Market Access in 2026: Medicare Negotiation, Spain Reform &amp; Portugal HTA\" \/>\n<meta property=\"og:description\" content=\"Explore the challenges of drug pricing and market access in a changing regulatory landscape. Understand the impact on commercialization.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/es\/precios-de-medicamentos-y-acceso-al-mercado-junio-de-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-30T02:41:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2026\/06\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Shaffa Renaningtyas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Shaffa Renaningtyas\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/\"},\"author\":{\"name\":\"Shaffa Renaningtyas\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/6d86c29c9123b2b67a3ea8e259cdb925\"},\"headline\":\"Drug Pricing &#038; Market Access in 2026: Medicare Neg&hellip;\",\"datePublished\":\"2026-06-30T02:41:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/\"},\"wordCount\":490,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png\",\"articleSection\":[\"Blogs\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/\",\"name\":\"Drug Pricing and Market Access Explained in 2026\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png\",\"datePublished\":\"2026-06-30T02:41:44+00:00\",\"description\":\"Explore the challenges of drug pricing and market access in a changing regulatory landscape. Understand the impact on commercialization.\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png\",\"width\":800,\"height\":600,\"caption\":\"Drug Pricing & Market Access In 2026 Medicare Negotiation, Spain Reform & Portugal Hta\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"The Regulatory AI Operating System for High-Performing Teams\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/6d86c29c9123b2b67a3ea8e259cdb925\",\"name\":\"Shaffa Renaningtyas\",\"sameAs\":[\"https:\\\/\\\/regask.com\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Precios de los medicamentos y acceso al mercado explicados en 2026","description":"Analice los desaf\u00edos que plantean los precios de los medicamentos y el acceso al mercado en un panorama regulatorio cambiante. Comprenda el impacto en la comercializaci\u00f3n.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/es\/precios-de-medicamentos-y-acceso-al-mercado-junio-de-2026\/","og_locale":"es_ES","og_type":"article","og_title":"Drug Pricing & Market Access in 2026: Medicare Negotiation, Spain Reform & Portugal HTA","og_description":"Explore the challenges of drug pricing and market access in a changing regulatory landscape. Understand the impact on commercialization.","og_url":"https:\/\/regask.com\/es\/precios-de-medicamentos-y-acceso-al-mercado-junio-de-2026\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2026-06-30T02:41:44+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/06\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png","type":"image\/png"}],"author":"Shaffa Renaningtyas","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Shaffa Renaningtyas","Est. reading time":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/#article","isPartOf":{"@id":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/"},"author":{"name":"Shaffa Renaningtyas","@id":"https:\/\/regask.com\/#\/schema\/person\/6d86c29c9123b2b67a3ea8e259cdb925"},"headline":"Drug Pricing &#038; Market Access in 2026: Medicare Neg&hellip;","datePublished":"2026-06-30T02:41:44+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/"},"wordCount":490,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/06\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png","articleSection":["Blogs"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/","url":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/","name":"Precios de los medicamentos y acceso al mercado explicados en 2026","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/06\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png","datePublished":"2026-06-30T02:41:44+00:00","description":"Analice los desaf\u00edos que plantean los precios de los medicamentos y el acceso al mercado en un panorama regulatorio cambiante. Comprenda el impacto en la comercializaci\u00f3n.","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/drug-pricing-market-access-june-2026\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/06\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/06\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png","width":800,"height":600,"caption":"Drug Pricing & Market Access In 2026 Medicare Negotiation, Spain Reform & Portugal Hta"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"El sistema operativo de IA regulatoria para equipos de alto rendimiento","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/6d86c29c9123b2b67a3ea8e259cdb925","name":"Shaffa Renaningtyas","sameAs":["https:\/\/regask.com\/"]}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts\/10377","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/users\/46"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/comments?post=10377"}],"version-history":[{"count":3,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts\/10377\/revisions"}],"predecessor-version":[{"id":10381,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts\/10377\/revisions\/10381"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/media\/10378"}],"wp:attachment":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/media?parent=10377"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/categories?post=10377"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/tags?post=10377"}],"curies":[{"name":"Gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}